Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spondylarthritis | 3 | 2025 | 6 | 1.970 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2025 | 677 | 1.190 |
Why?
|
| Hypophysitis | 1 | 2021 | 1 | 0.710 |
Why?
|
| Gout Suppressants | 1 | 2021 | 35 | 0.690 |
Why?
|
| Gout | 1 | 2021 | 75 | 0.680 |
Why?
|
| Scleroderma, Systemic | 4 | 2026 | 53 | 0.640 |
Why?
|
| Rheumatic Diseases | 1 | 2018 | 37 | 0.530 |
Why?
|
| Crohn Disease | 1 | 2025 | 844 | 0.530 |
Why?
|
| Colitis, Ulcerative | 1 | 2025 | 824 | 0.520 |
Why?
|
| Connective Tissue Diseases | 1 | 2018 | 76 | 0.520 |
Why?
|
| Skin Diseases | 1 | 2018 | 176 | 0.480 |
Why?
|
| Piperazines | 3 | 2011 | 306 | 0.420 |
Why?
|
| Affect | 3 | 2011 | 410 | 0.350 |
Why?
|
| Prevalence | 3 | 2025 | 1384 | 0.350 |
Why?
|
| Heart Failure | 1 | 2022 | 1491 | 0.340 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2010 | 14 | 0.320 |
Why?
|
| Hallucinogens | 1 | 2010 | 92 | 0.280 |
Why?
|
| Receptor, Notch4 | 1 | 2026 | 6 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 1 | 2026 | 356 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2037 | 0.200 |
Why?
|
| Humans | 17 | 2026 | 98088 | 0.190 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3022 | 0.190 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2022 | 20 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 41 | 0.180 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 11 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 98 | 0.180 |
Why?
|
| Canada | 1 | 2022 | 211 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 111 | 0.170 |
Why?
|
| Sex Factors | 1 | 2025 | 1138 | 0.170 |
Why?
|
| Uric Acid | 1 | 2021 | 137 | 0.170 |
Why?
|
| Aftercare | 1 | 2022 | 91 | 0.170 |
Why?
|
| Rituximab | 1 | 2021 | 135 | 0.170 |
Why?
|
| Analgesics | 1 | 2021 | 131 | 0.160 |
Why?
|
| Smoking | 1 | 2025 | 674 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 2 | 2015 | 246 | 0.160 |
Why?
|
| Age Factors | 1 | 2025 | 1962 | 0.150 |
Why?
|
| Molecular Mimicry | 1 | 2019 | 17 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2025 | 3212 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2022 | 464 | 0.150 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 480 | 0.150 |
Why?
|
| Mass Screening | 1 | 2025 | 745 | 0.150 |
Why?
|
| Renal Dialysis | 1 | 2022 | 357 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2022 | 381 | 0.140 |
Why?
|
| Autoantigens | 1 | 2019 | 145 | 0.140 |
Why?
|
| Autoantibodies | 1 | 2019 | 286 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2019 | 238 | 0.140 |
Why?
|
| Sjogren's Syndrome | 1 | 2018 | 34 | 0.140 |
Why?
|
| Adult | 8 | 2026 | 29539 | 0.130 |
Why?
|
| Fatigue | 1 | 2018 | 187 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2026 | 2555 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 1122 | 0.120 |
Why?
|
| Male | 11 | 2026 | 47077 | 0.120 |
Why?
|
| United States | 3 | 2025 | 8197 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 337 | 0.110 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2015 | 29 | 0.110 |
Why?
|
| Basal Ganglia | 1 | 2015 | 47 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1110 | 0.110 |
Why?
|
| von Willebrand Diseases | 1 | 2014 | 4 | 0.100 |
Why?
|
| Carrier State | 1 | 2014 | 40 | 0.100 |
Why?
|
| Risk Factors | 1 | 2025 | 6233 | 0.100 |
Why?
|
| Methamphetamine | 1 | 2015 | 111 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2014 | 471 | 0.100 |
Why?
|
| Middle Aged | 5 | 2026 | 29428 | 0.100 |
Why?
|
| Female | 9 | 2026 | 51541 | 0.090 |
Why?
|
| Genetic Linkage | 1 | 2014 | 613 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 548 | 0.090 |
Why?
|
| Pharmacy Technicians | 1 | 2011 | 1 | 0.080 |
Why?
|
| Physiological Phenomena | 1 | 2011 | 7 | 0.080 |
Why?
|
| Pharmaceutical Services | 1 | 2011 | 9 | 0.080 |
Why?
|
| Professional Role | 1 | 2011 | 40 | 0.080 |
Why?
|
| Pharmacists | 1 | 2011 | 42 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 402 | 0.080 |
Why?
|
| Haplotypes | 1 | 2026 | 656 | 0.050 |
Why?
|
| New Zealand | 2 | 2011 | 24 | 0.040 |
Why?
|
| Mimiviridae | 1 | 2019 | 1 | 0.040 |
Why?
|
| Phycodnaviridae | 1 | 2019 | 2 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 84 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2019 | 123 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2019 | 403 | 0.040 |
Why?
|
| Phenotype | 1 | 2026 | 2638 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2019 | 340 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2026 | 2573 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2018 | 114 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 170 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2018 | 141 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1159 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2019 | 2006 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 614 | 0.030 |
Why?
|
| Putamen | 1 | 2015 | 15 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 663 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2026 | 3620 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2017 | 1061 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 78 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2014 | 31 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 271 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2015 | 226 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2014 | 90 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1094 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2014 | 263 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 980 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2585 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2013 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 1445 | 0.020 |
Why?
|
| Mice | 1 | 2026 | 12706 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 127 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 201 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 7507 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 10080 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 376 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 401 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 508 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 889 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 4823 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 534 | 0.020 |
Why?
|
| Anxiety | 1 | 2011 | 370 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1950 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1782 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 910 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 601 | 0.010 |
Why?
|
| Animals | 1 | 2026 | 28904 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 685 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 10973 | 0.010 |
Why?
|